Patents by Inventor Timothy Hoey
Timothy Hoey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110311552Abstract: Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject.Type: ApplicationFiled: July 8, 2009Publication date: December 22, 2011Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Publication number: 20110195065Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: January 20, 2011Publication date: August 11, 2011Inventors: John A. LEWICKI, Austin GURNEY, Timothy HOEY, Wan-Ching YEN, Sanjeev SATYAL
-
Patent number: 7919092Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: GrantFiled: May 31, 2007Date of Patent: April 5, 2011Assignee: OncoMed Pharmaceuticals, Inc.Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-Ching Yen, Sanjeev Satyal
-
Publication number: 20100317098Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: ApplicationFiled: March 15, 2010Publication date: December 16, 2010Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Patent number: 7723477Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: GrantFiled: October 31, 2006Date of Patent: May 25, 2010Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Publication number: 20080317760Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: ApplicationFiled: May 15, 2008Publication date: December 25, 2008Inventors: Austin GURNEY, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Publication number: 20080131434Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: May 31, 2007Publication date: June 5, 2008Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-Ching Yen, Sanjeev Satyal
-
Publication number: 20070117751Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: ApplicationFiled: October 31, 2006Publication date: May 24, 2007Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Publication number: 20070116701Abstract: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.Type: ApplicationFiled: October 31, 2006Publication date: May 24, 2007Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Publication number: 20050152896Abstract: The present invention provides antibodies that immunospecifically bind to a galanin peptide and compositions comprising said antibodies. The present invention also provides methods for preventing, treating, managing, and/or ameliorating hyperproliferative disorders or a symptom thereof comprising administering to a subject in need thereof one or more antibodies that immunospecifically bind to a galanin peptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing hyperproliferative disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to a galanin peptide.Type: ApplicationFiled: December 10, 2004Publication date: July 14, 2005Applicant: Amgen Inc.Inventors: Wade Aaron, Richard Austin, Cynthia Hart, Timothy Hoey, Paul Kassner, Derek Piper, Anthony Slavin
-
Patent number: 5756700Abstract: The invention provides methods and compositions relating to interleukin 12 signal transducers, particularly an isolated human signal transducer and activator of transcription 4 (hStat 4), or a fragment thereof having an hStat 4-specific binding affinity, nucleic acids encoding hStat 4, which nucleic acids may be part of hStat 4-expression vectors and may be incorporated into a recombinant cell, agents which selectively bind hStat 4 or hStat 4 intracellular binding targets, or disrupt the binding of hStat 4 to such intracellular targets, methods of making such agents and hStat 4-specific binding targets in the form of cell surface proteins and nucleic acids. An hStat 4 drug screening assay involves forming mixtures of an hStat 4, an intracellular hStat 4 binding target, and a prospective agent at different concentrations. The mixtures are incubated to permit the binding of the intracellular hStat 4 binding target to the hStat 4 and the mixtures are then analyzed for the presence of such binding.Type: GrantFiled: April 23, 1997Date of Patent: May 26, 1998Assignee: Tularik Inc.Inventors: Timothy Hoey, Mike Rothe
-
Patent number: 5708158Abstract: The invention provides methods and compositions for identifying pharmacological agents useful in the diagnosis or treatment of disease associated with the expression of a gene modulated by a transcription complex containing at least a human nuclear factor of activated T-cells (hNFAT). The materials include a family of hNFAT proteins, active fragments thereof, and nucleic acids encoding them. The methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromechanical robot comprising an axial rotatable arm.Type: GrantFiled: March 14, 1997Date of Patent: January 13, 1998Assignee: Tularik Inc.Inventor: Timothy Hoey
-
Patent number: 5639858Abstract: The invention provides methods and compositions relating to interleukin 12 signal transducers, particularly an isolated human signal transducer and activator of transcription 4 (hStat 4), or a fragment thereof having an hStat 4-specific binding affinity, nucleic acids encoding hStat 4, which nucleic acids may be part of hStat 4-expression vectors and may be incorporated into a recombinant cell, agents which selectively bind hStat 4 or hStat 4 intracellular binding targets, or disrupt the binding of hStat 4 to such intracellular targets, methods of making such agents and hStat 4-specific binding targets in the form of cell surface proteins and nucleic acids. An hStat 4 drug screening assay involves forming mixtures of an hStat 4, an intracellular hStat 4 binding target, and a prospective agent at different concentrations. The mixtures are incubated to permit the binding of the intracellular hStat 4 binding target to the hStat 4 and the mixtures are then analyzed for the presence of such binding.Type: GrantFiled: March 22, 1995Date of Patent: June 17, 1997Assignee: Tularik, Inc.Inventors: Timothy Hoey, Mike Rothe
-
Patent number: 5637686Abstract: TATA-binding protein associated factors, TAFs, nuclear proteins involved in RNA polymerase I, II, and III transcription, and nucleic acids encoding TAFs are disclosed. The disclosed methods and compositions find use in developing pharmaceuticals, diagnosis and therapy.Type: GrantFiled: May 9, 1996Date of Patent: June 10, 1997Assignee: The Regents of the University of CaliforniaInventors: Robert Tjian, Lucio Comai, Brian D. Dynlact, Timothy Hoey, Siegfried Ruppert, Naoko Tanese, Edith Wang, Robert O. J. Weinzierl
-
Patent number: 5612455Abstract: The invention provides methods and compositions for identifying pharmacological agents useful in the diagnosis or treatment of disease associated with the expression of a gene modulated by a transcription complex containing at least a human nuclear factor of activated T-cells (hNFAT). The materials include a family of hNFAT proteins, active fragments thereof, and nucleic acids encoding them. The methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromechanical robot comprising an axial rotatable arm.Type: GrantFiled: March 2, 1995Date of Patent: March 18, 1997Assignee: Tularik, Inc.Inventor: Timothy Hoey
-
Patent number: 5534410Abstract: TATA-binding protein associated factors, TAFs, nuclear proteins involved in RNA polymerase I, II, and III transcription, and nucleic acids encoding TAFs are disclosed. The disclosed methods and compositions find use in developing pharmaceuticals, diagnosis and therapy.Type: GrantFiled: January 28, 1994Date of Patent: July 9, 1996Assignee: The Regents of the University of CaliforniaInventors: Robert Tjian, Lucio Comai, Brian D. Dynlacht, Timothy Hoey, Siegfried Ruppert, Naoko Tanese, Edith Wang, Robert O. J. Weinzierl